Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Pizza, beer, and peptides on offer at scientists' social hours

Kendall Squared brings you dispatches from the world’s epicenter for biotechnology and drug discovery. On the face of it, the event last month looked like a standard networking to-do: people from different companies streaming to the same spot after work, grabb

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Kendall Squared brings you dispatches from the world’s epicenter for biotechnology and drug discovery.

On the face of it, the event last month looked like a standard networking to-do: people from different companies streaming to the same spot after work, grabbing beers and slices of pizza as they caught up. But as people milled about, they stopped and perused posters outlining scientific studies. They dived into conversations about their latest lab findings. Soon, they sat down to hear a presentation about the role of a signaling pathway in retinal rods and cones. It may not have fit everyone’s definition of an exciting way to kick back after a day on the job. But the event has become a social ritual for local scientists. It was the latest of the so-called Cyclic GMP Forums, named for the small molecule that fills important jobs throughout the body, from muscle relaxation to how the eye responds to light. The forums — which typically include talks, poster presentations, and plenty of mingling — serve as an informal way for scientists across industry and academia who study related fields to catch up on cutting-edge research and bounce possible solutions to shared problems off each other. “It feels a little bit like a reunion,” said Todd Milne, a vice president at Ironwood Pharmaceuticals who helped launch the forums last year. “These are people who care about things you care about.” Plus, the room is filled with people who can banter about the intricacies of their research area as fluently as if they were gabbing about the Patriots’ injury woes or their new year’s resolutions. “I can tell my mother all about (cyclic GMP), but she’s not going to care … about some of the details,” Milne said. At the recent cyclic GMP event, held at Ironwood, a company scientist chatted with a Massachusetts General Hospital researcher about the results of a blood pressure study in an animal model. A talk that night from a researcher at Massachusetts Eye and Ear was largely unintelligible to a non-scientist, but most of the people listening seemed relatively rapt by the presentation. A similar series of events focused on peptide research called PEPtalks started in 2013 and now, like the Cyclic GMP Forums, takes place quarterly. Plenty of other regular biotech social gatherings exist, including networking event Biotech Tuesday and a biotech softball league, where players have been known to talk study design and regulatory guidelines on the diamond. What’s different about series like the peptide and cyclic GMP events is their focus on specific areas of science. The events strike a casual atmosphere, but high-level conversations that wouldn’t be out of place in a lab abound. In this case, however, the people talking might be holding Ballast Point beers, not beakers. For Dr. Christopher Newton-Cheh, a Mass General cardiologist who helps organize the Cyclic GMP Forum, the events have been instructional not just scientifically but professionally. “It’s an education in how pharmaceutical companies and biotechnology companies develop these drugs and how they identify what the potential stumbling blocks are,” he said. Obviously, industry scientists who attend keep their companies’ proprietary information to themselves. But the events enable scientists to keep up with research going on locally that may not be ready for the prime time of a conference or journal but that still has salience to fellow devotees of the field. “Sometimes people will present things that they just found in the lab last week,” said Yvonne Angell, who helps organize PEPtalks. Angell, a biotech consultant and founder of Picotide Technologies, said the organizers saw a need to bring together the loose community of scientists studying peptides in drug development. Twenty-five or so people showed up to the first event, but word of the PEPtalks has spread through conferences and people telling their coworkers, attracting about 100 people to the most recent one. They’ve been held at Novartis, Ironwood, and Ipsen. “It’s almost running itself there’s so much enthusiasm,” Angell said, adding that potential speakers are now asking her if they can present. The ninth PEPtalks, which is open to any researcher, will take place Thursday at Merck Research Laboratories in Boston. On the agenda: a talk from a New York University chemist about protein-protein interactions and one from a Merck scientist called “Peptide Drug Hunter.” Past speakers at PEPtalks included researchers from Tufts, Northeastern, and the City University of New York, as well as scientists from Novartis, Cubist Pharmaceuticals, and Ensemble Therapeutics. Tarik Soliman, chief executive of Extend Biosciences, a company working to improve how long peptide-based drugs can last in the body, said he has been to five of the PEPtalks. Peptides have tons of unmet potential in drug development, he said, so the events allow scientists from across the field to try to work out some of the common hurdles. “There have been very few peptides that have made it to the market — everyone’s trying to work out the problems,” he said. “This little niche group has been really fun to interact with.” Milne agreed. With the first PEPtalk, which he also helped plan, Milne didn’t know what to expect — he referred to it as an “experiment.” But the proof of people’s engagement came as attendance kept growing. “Seeing everybody show up and be really excited about talking about peptides — it was striking,” he said.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How Real Brain Cells Respond to Artificial Neurons

Holla, who completed her PhD in Raman’s lab and is now a postdoctoral researcher studying memory at New York University in New York City, designed and ran experiments in mouse cerebellar slices. She positioned a stimulation electrode on the parallel fibers, the main pathway that excites Purkinje cells, and a recording electrode on the Purkinje cells themselves. She played recordings of the artificial neurons’ waveforms into the tissue through a standard stimulation electrode at four different speeds: 7, 60, 218, and 740 spikes per second. At every speed below 200 spikes per second, the Purkinje cells fired in response. The strongest results came at 60 spikes per second, where each artificial spike lasted 0.7 milliseconds, which is fast enough to trigger the cell but brief enough to avoid flooding the tissue with unnecessary current. Above 200 spikes per second, the cells stopped responding. They simply cannot fire that fast. The team included the 740-spikes-per-second condition on purpose to directly challenge the many engineering groups building artificial neurons that operate at those speeds. “We had to show them [740 spikes] wasn’t sufficient,” Brown said. “You can’t work that fast.” “You can see the living neurons respond to our artificial neuron,” Hersam said. But he is careful to note a caveat: The printed artificial neurons were not touching the brain tissue. The waveforms they generated were recorded and then played back into the slice through standard laboratory stimulation equipment. The next step is to prove the printed device itself can interface with living tissue.

Source: www.medscape.com ↗
02Why Muscle Cells Might Do Some Heavy Lifting

Brown was studying gene therapy in the 1990s when he designed a technology to turn mRNA expression on or off in different cells. For the new mouse study, published in Nature Biotechnology , he adapted the technology to turn off mRNA expression in dendritic cells, muscle cells, or liver cells. The researchers then vaccinated the mice with each version, delivering the vaccines both intravenously and intramuscularly. “The results were pretty stunning,” Brown said. When mRNA expression was turned off in muscle cells, T-cell response went down, suggesting muscle cells play a role in immunity. When expression was turned off in liver cells, T-cell expression tripled — indicating liver cells dampen immunity. Turning off expression in dendritic cells had no effect on T-cell activation, though it did reduce the number of killer T cells by as much as half. (Interestingly, no such reduction occurred when the antigen was SARS-CoV-2 spike. Brown is now investigating why different antigens had varying effects.) Knowing all this is crucial for designing effective mRNA vaccines and therapies. That’s because different mRNA therapies require different strategies. Cancer vaccines must boost tumor-fighting killer (CD8+) T cells. For genetic disease treatments, scientists want to avoid triggering the immune system to prevent killing the very cells the mRNA is meant to modify. “Understanding the immunology is extremely important for this class of drug,” Brown said. The finding doesn’t mean dendritic cells aren’t important for mRNA vaccines to work. “It just means that the mRNA doesn’t have to get into those cells to induce an immune response,” Brown said. Instead, the antigen can be transferred to those dendritic cells.

Source: www.medscape.com ↗
03China: Threat or opportunity?

One of the biggest biotech news stories of recent years is China’s continued rise as a biotech and life sciences powerhouse. China conducts a quarter of all clinical trials and drug development and has almost 1,500 new drugs in development.¹ Many China-based biotechs have benefitted from government funds, out-licencing deals with large pharmas and venture capital funding. However, policymakers in the US and EU have concerns about the possible threat to their region’s biosecurity and competitiveness as centres for health and life science research. Given China’s increased importance, ICON Biotech conducted the same biotech sector survey with 100 China-based biotech leaders. The results show that Chinese biotechs face many of the same challenges as biotechs located elsewhere. They share the same funding challenges and burdens associated with increasingly complex clinical trials and regulations.

Source: www.biopharmadive.com ↗
04Lifestyle Matters: How do environmental and lifestyle factors influence Alzheimer’s disease?

Dr. Harrison and Finnish neuroscientist Dr. Miia Kivipelto explore the complex interplay between genetics and lifestyle in Alzheimer's development. Learn how the groundbreaking FINGER study demonstrates potential prevention strategies, and discover the latest evidence on how environmental factors, diet, and chronic conditions influence Alzheimer's risk.

Source: www.biopharmadive.com ↗
05What Comes Next

With data expected in the fourth quarter of 2026, we are prioritizing histology alongside patient-reported outcomes using the Celiac Disease Symptom Diary, one of only two instruments developed in line with U.S. Food and Drug Administration (FDA) guidance, to capture changes in symptoms such as abdominal pain and nausea. Ultimately, the broader aim is to give gastroenterologists and patients a therapeutic option for a disease that has long been managed without one. The future of drug development will not be defined by statistical significance alone, but by whether new therapies also improve the daily burden of living with celiac disease. “The first therapy to cross the line could change the field,” Geller concluded. “It would help establish celiac as a serious medical condition with options beyond a restrictive diet and open the door for what comes next.” Dr. Paul Lizzul is chief medical officer at First Tracks Biotherapeutics, a clinical ‑ stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. Marilyn Geller serves as an advisor to First Tracks Bio. Footnotes Abadie V, Jabri B. IL-15: a central regulator of celiac disease immunopathology. Immunol Rev . 2014;260(1):221-234. https://doi.org/10.1111/imr.12191. Yokoyama S, Watanabe N, Sato N, et al. Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytes. Proc Natl Acad Sci U S A . 2009;106(37):15849-15854. https://doi/full/10.1073/pnas.0908834106. Anthony S, Schluns KS. Emerging roles for IL-15 in the activation and function of T-cells during immune stimulation. Research and Reports in Biology . 2015;6:25-37. https://doi.org/10.2147/RRB.S57685.

Source: www.biopharmadive.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →